Stockscreener 앱 받기
8.49
1.68%
0.14
시간 외 거래:
8.49
전일 마감가:
$8.35
열려 있는:
$8.36
하루 거래량:
364.42K
Relative Volume:
0.17
시가총액:
$521.60M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-3.3035
EPS:
-2.57
순현금흐름:
$-67.76M
1주 성능:
+9.69%
1개월 성능:
+59.89%
6개월 성능:
+101.66%
1년 성능:
+184.90%
1일 변동 폭
$8.24
$8.67
1주일 범위
$7.40
$8.90
52주 변동 폭
$2.9106
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
GLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| GLUE | 8.49 | 521.60M | 0 | -130.41M | -67.76M | -2.57 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire
Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan
FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance
Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World
Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks
Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart
Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan
Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World
Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online
Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance
Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma
Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance
This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal
Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada
Novartis adds another degrader, this time from Monte Rosa - BioCentury
This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat
Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha
Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals
Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart
Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India
Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online
Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters
Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance
Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):